Published in Am J Psychiatry on August 01, 2003
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull (2009) 4.69
Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull (2009) 1.52
Methodological issues in negative symptom trials. Schizophr Bull (2011) 1.28
Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry (2011) 1.07
Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evid (2008) 0.83
Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. Psychopharmacology (Berl) (2011) 0.80
Antipsychotic agents: efficacy and safety in schizophrenia. Drug Healthc Patient Saf (2012) 0.79
Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study. Croat Med J (2008) 0.78
Long-Term Aripiprazole in Youth With Developmental Disabilities Including Autism. J Ment Health Res Intellect Disabil (2011) 0.76
The therapeutic effectiveness of risperidone on negative symptoms of schizophrenia in comparison with haloperidol: a randomized clinical trial. Basic Clin Neurosci (2014) 0.75
Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry (2006) 5.30
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry (2007) 2.91
Brief cognitive-behavioral therapy effects on post-treatment suicide attempts in a military sample: results of a randomized clinical trial with 2-year follow-up. Am J Psychiatry (2015) 2.80
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry (2002) 2.70
Genomewide linkage analyses of bipolar disorder: a new sample of 250 pedigrees from the National Institute of Mental Health Genetics Initiative. Am J Hum Genet (2003) 2.55
Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry (2011) 2.47
Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry (2007) 2.47
A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry (2007) 2.45
Randomized trial of trauma-focused group therapy for posttraumatic stress disorder: results from a department of veterans affairs cooperative study. Arch Gen Psychiatry (2003) 2.32
Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiol Aging (2004) 2.23
Family-focused treatment versus individual treatment for bipolar disorder: results of a randomized clinical trial. J Consult Clin Psychol (2003) 2.20
Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry (2008) 2.17
Consistency of Brief Psychiatric Rating Scale factor structure across a broad spectrum of schizophrenia patients. Psychopathology (2007) 2.01
White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Arch Neurol (2003) 1.93
Lifespan trajectory of myelin integrity and maximum motor speed. Neurobiol Aging (2008) 1.92
Is emotion processing a predictor of functional outcome in schizophrenia? Schizophr Bull (2003) 1.89
The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull (2006) 1.88
Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging (2006) 1.87
Increased amygdala activation during mania: a functional magnetic resonance imaging study. Am J Psychiatry (2005) 1.84
Conceptualizing impulsivity and risk taking in bipolar disorder: importance of history of alcohol abuse. Bipolar Disord (2009) 1.82
Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res (2006) 1.80
Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biol Psychiatry (2004) 1.72
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull (2007) 1.72
The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry (2002) 1.68
Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord (2011) 1.67
Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res (2007) 1.63
Schizophrenia as one extreme of a sexually selected fitness indicator. Schizophr Res (2004) 1.61
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry (2002) 1.55
Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol (2007) 1.54
Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull (2009) 1.52
Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin. Biol Psychiatry (2002) 1.47
Blunted activation in orbitofrontal cortex during mania: a functional magnetic resonance imaging study. Biol Psychiatry (2005) 1.44
Challenges to implementing and sustaining comprehensive mental health service programs. Eval Health Prof (2006) 1.39
Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull (2011) 1.38
Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology (2007) 1.33
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry (2007) 1.32
Neuropsychological deficits among patients with late-onset minor and major depression. Arch Clin Neuropsychol (2003) 1.30
A videotape intervention to enhance the informed consent process for medical and psychiatric treatment research. Am J Psychiatry (2005) 1.29
Computer-assisted self-assessment in persons with severe mental illness. J Clin Psychiatry (2004) 1.28
Do the siblings of schizophrenia patients demonstrate affect perception deficits? Schizophr Res (2004) 1.27
Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. Neuropsychopharmacology (2006) 1.27
Bipolar pharmacotherapy and suicidal behavior. Part I: Lithium, divalproex and carbamazepine. J Affect Disord (2007) 1.26
Neuropsychiatric predictors of return to work in HIV/AIDS. J Int Neuropsychol Soc (2007) 1.25
Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res (2006) 1.25
Regional brain changes in bipolar I depression: a functional magnetic resonance imaging study. Bipolar Disord (2008) 1.25
Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry (2006) 1.24
Improving informed consent: the medium is not the message. IRB (2004) 1.23
Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia. Arch Gen Psychiatry (2006) 1.22
Gray matter prefrontal changes in type 2 diabetes detected using MRI. J Magn Reson Imaging (2008) 1.22
Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry (2002) 1.22
Brain maturation may be arrested in chronic cocaine addicts. Biol Psychiatry (2002) 1.20
Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs (2007) 1.18
Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenon. Arch Gen Psychiatry (2005) 1.16
Multimodal magnetic resonance imaging assessment of white matter aging trajectories over the lifespan of healthy individuals. Biol Psychiatry (2012) 1.15
Conducting empirical research on informed consent: challenges and questions. IRB (2004) 1.14
Disease management in Latinos with schizophrenia: a family-assisted, skills training approach. Schizophr Bull (2003) 1.13
Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry (2006) 1.13
A controlled trial of cognitive remediation in schizophrenia. Schizophr Bull (2002) 1.13
In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr Res (2009) 1.12
Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study. Biol Psychiatry (2003) 1.12
Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res (2007) 1.11
Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia. Schizophr Bull (2008) 1.11
Human brain myelination and amyloid beta deposition in Alzheimer's disease. Alzheimers Dement (2007) 1.10
Visual masking as a probe for abnormal gamma range activity in schizophrenia. Biol Psychiatry (2003) 1.10
Quantifying age-related myelin breakdown with MRI: novel therapeutic targets for preventing cognitive decline and Alzheimer's disease. J Alzheimers Dis (2004) 1.09
Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry (2005) 1.09
Apolipoprotein E affects both myelin breakdown and cognition: implications for age-related trajectories of decline into dementia. Biol Psychiatry (2007) 1.08
A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophrenia. Schizophr Bull (2012) 1.07
Impaired implicit learning in schizophrenia. Neuropsychology (2008) 1.07
Stressful life events in recent-onset schizophrenia: reduced frequencies and altered subjective appraisals. Schizophr Res (2005) 1.06
Forward and backward visual masking in unaffected siblings of schizophrenic patients. Biol Psychiatry (2005) 1.05
Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy. Am J Psychiatry (2002) 1.05
Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents. Am J Psychiatry (2003) 1.05
Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord (2007) 1.05
Bipolar pharmacotherapy and suicidal behavior Part 3: impact of antipsychotics. J Affect Disord (2007) 1.04
Bipolar pharmacotherapy and suicidal behavior Part 2. The impact of antidepressants. J Affect Disord (2007) 1.04
A network-based system to improve care for schizophrenia: the Medical Informatics Network Tool (MINT). J Am Med Inform Assoc (2004) 1.04
Applications of errorless learning for improving work performance in persons with schizophrenia. Am J Psychiatry (2002) 1.03
The cultural adaptability of intermediate measures of functional outcome in schizophrenia. Schizophr Bull (2010) 1.02
Extensions of errorless learning for social problem-solving deficits in schizophrenia. Am J Psychiatry (2005) 1.02
Sex differences in brain structure in geriatric depression. Am J Geriatr Psychiatry (2004) 1.02
Paracontrast and metacontrast in schizophrenia: clarifying the mechanism for visual masking deficits. Schizophr Res (2004) 1.02
Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res (2012) 1.01
Evaluation of expressed emotion in schizophrenia: a comparison of Caucasians and Mexican-Americans. Schizophr Res (2002) 1.01
Intranasal quetiapine abuse. Am J Psychiatry (2004) 1.01
Executive dysfunction and memory in older patients with major and minor depression. Arch Clin Neuropsychol (2007) 0.99
Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res (2011) 0.99
Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. Bipolar Disord (2010) 0.99